Viewing Study NCT06539559

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 2:52 PM
Ignite Modification Date: 2026-02-03 @ 3:18 AM
Study NCT ID: NCT06539559
Status: NOT_YET_RECRUITING
Last Update Posted: 2024-08-06
First Post: 2024-07-28
Is Gene Therapy: True
Has Adverse Events: False
Brief Title: Efficacy and Resistant Mechanism of Eribulin and Bevacizumab for Advanced HER2 Negative Breast Cancer
Sponsor: Wang Jiayu
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Breast Neoplasms View
None Neoplasm Metastasis View
None Drug Therapy View
None Bevacizumab View
Keywords:

Keywords

Keyword Brief Keyword Text View
None breast cancer View
None HER2 negative View
None eribulin View
None bevacizumab View
None efficacy View
None resistant mechanism View